Cirrhotic cardiomyopathy and hepatopulmonary syndrome: Prevalence and prognosis in a series of patients  by Enache, Irina et al.
Respiratory Medicine (2013) 107, 1030e1036Available online at www.sciencedirect.com
journal homepage: www.elsevier .com/locate /rmedCirrhotic cardiomyopathy and
hepatopulmonary syndrome: Prevalence
and prognosis in a series of patientsIrina Enache a,d, Monique Oswald-Mammosser a,e,
Marie-Lorraine Woehl-Jaegle b,f, Franc¸ois Habersetzer c,g,
Paola Di Marco a,h, Anne Charloux a,i, Ste´phane Doutreleau a,*a Service de Physiologie et d’Explorations Fonctionnelles, Poˆle de Pathologie Thoracique,
Hoˆpitaux Universitaires de Strasbourg, Nouvel Hoˆpital Civil, B.P. 426, 67091 Strasbourg Cedex, France
b Service de Chirurgie et de Transplantations Multiorganes, Poˆle des Pathologies
Digestives-He´patiques-Transplantations, Hoˆpitaux Universitaires de Strasbourg, France
c Service d’He´pato-Gastro-Ente´rologie, Poˆle He´pato-digestif de l’Hoˆpital Civil,
Hoˆpitaux Universitaires de Strasbourg, FranceReceived 24 November 2012; accepted 11 March 2013
Available online 21 April 2013KEYWORDS
Carbon monoxide;
Cirrhotic
cardiomyopathy;
Diastolic dysfunction;
Liver disease;
Hepatopulmonary
syndrome* Corresponding author. Tel.: þ33 3
E-mail addresses: irina.enache@c
lorraine.woehl@chru-strasbourg.fr (
marco@chru-strasbourg.fr (P. Di Mar
Doutreleau).
d Tel.: þ33 369550662.
e. Tel.: þ33 369550659.
f Tel.: þ33 388127280.
g. Tel.: þ33 369551009.
h Tel.: þ33 369551182.
i Tel.: þ33 369550878.
0954-6111/$ - see front matter ª 201
http://dx.doi.org/10.1016/j.rmed.20Summary
Hepatopulmonary syndrome (HPS) is of prognostic value in patients awaiting for orthotopic
liver transplantation (OLT), but little is known about the effect of cirrhotic cardiomyopathy
(CCM). The aim of the present study was to estimate the prevalence and possible relation be-
tween respiratory and cardiac abnormalities in a same series of patients awaiting OLT. Special
attention was paid to the prognostic value of CCM in comparison to HPS.
Eighty-three patients were included (19 females, 64 males; 52.1  10.0 yrs). All had lung
function testing with arterial blood gases and echocardiographic evaluation at rest with a
contrast echocardiography in case of arterial oxygenation defect. To estimate the presence
of CCM, patients underwent a complete left and right echocardiography and Doppler69551303; fax: þ33 369551826.
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Intrapulmonary shunt in liver diseases 1031examination. Complete echocardiographic assessment could be obtained in 64 of the 83 pa-
tients of the study.
HPS was observed in 16.9% (14/83) and CCM in 23.4% (15/64) of patients. There was a ten-
dency of more serious adverse events before and after OLT in patients with HPS in comparison
to others but CCM was not of prognostic value.
HPS and CCM were frequent in these patients awaiting OLT but both abnormalities were not
found in the same patients. CCM was neither related to death before OLT nor to death or
serious adverse events after OLT.
ª 2013 Published by Elsevier Ltd.Introduction
Liver diseases are associated with pulmonary complications
in a significant number of patients.1,2 The most common
complication is hepatopulmonary syndrome (HPS), which is
defined as a defect in arterial oxygenation due to intra-
pulmonary vascular dilatation in the setting of liver dis-
ease,3,4 and is found in 10e30% of candidates for liver
transplantation. Diagnosing this complication is essential,
as it has been associated with pre- and post-transplantation
mortality.5e7 Portopulmonary hypertension (PPH) is less
common (in 3e5% of cases1) and is defined as the combi-
nation of pulmonary and portal hypertension.8,9
In addition to these pulmonary complications, purely
cardiovascular complications, such as cirrhotic cardiomy-
opathy (CCM), have also been reported. CCM is defined as a
cardiac dysfunction characterized by blunted contractile
responsiveness to stress and/or diastolic dysfunction at rest
and/or electrical conductance abnormalities (prolonged QT
interval corrected for heart rate (QTc)) in the absence of
other known cardiac disease.10e13 Orthotopic liver trans-
plantation (OLT) has been reported to reverse some alter-
ations, specifically diastolic dysfunction and the increase in
wall thickness, as assessed by echocardiography.14e18 The
prevalence of CCM is not accurately known, and to the best
of our knowledge, its prognostic value for mortality and
morbidity has not previously been estimated.
The exact mechanisms leading to HPS and CCM are still
not completely understood but an overproduction of nitric
oxide (NO) and carbon monoxide has been suspected to
play a role.10,11,15,19e21 Thus, it might be helpful to deter-
mine whether HPS and CCM occur in the same patients, and
if their eventual coexistence may influence the prognosis of
patients awaiting OLT.
Therefore, the aims of our study were i) to determine
the prevalence and prognostic value of HPS and CCM in
patients with liver disease awaiting OLT; and ii) to assess
whether CCM is more common in patients presenting with
HPS, which could also influence their prognoses.Materials and methods
Eighty-three consecutive candidates for OLT (19 women
and 64 men, aged 51.7  2.5 and 53.5  1.2 years, with a
body mass index of 25.4  1 and 27.1  0.6, respectively)
were included in the study. Forty-one patients had alco-
holic cirrhosis, 16 had hepatitis C, eight had hepatitis B,four had primary biliary cirrhosis, and two had secondary
biliary cirrhosis. Four patients presented with hepatitis B or
C or biliary cirrhosis and abusive alcohol consumption. The
eight remaining patients presented with less common liver
diseases. On the same day, a complete medical history and
physical examination were performed, before the assess-
ment and recording of all participants’ pulmonary and
cardiac parameters.
The severity of liver disease was graded using the model
for end-stage liver disease (MELD) score.22
Based on coronary angiography or nuclear myocardial
perfusion imaging, severe stable ischemic heart disease was
observed in nine patients (none of whom were in the HPS
group, see below). Sixty-four patients were receiving
medical therapy in the form of beta-blockers and/or di-
uretics, or other antihypertensive treatments.
Informed consent was obtained from each patient. This
study protocol conformed to the ethical guidelines of the
1975 Declaration of Helsinki, and was approved by the
Institutional Review Board of the French Learned Society
for Respiratory Medicine (Socie´te´ de Pneumologie de Lan-
gue Franc¸aise; CEPRO 2010-002).
Pulmonary function testing
Lung volume, flowevolume curves, and diffusing capacity
for carbon monoxide (DLCO) were determined with a Jaeger
device (MasterScreen PFT, Jaeger GmbH, Wu¨rzburg,
Germany). The European Coal and Steel Community refer-
ence values were used.23 Exhaled NO was measured before
spirometry with a NIOX device (Aerocrine AB, Solna,
Sweden) at an expiration rate of 50 mL min1 after a deep
breath. Arterial blood gases (ABL725, Radiometer, Copen-
hagen, Denmark) were measured in the sitting position,
exhaled gases were analyzed, and AaPO2 was calculated
using the simplified alveolar gas equation.24
Electrocardiographic and echocardiographic
measurements
A conventional electrocardiogram (ECG) was performed at
rest on the same day. QT interval duration was automati-
cally determined from the beginning of the QRS complex to
the end of the T wave. The QTc was calculated using
Bazett’s formula. A QTc > 440 ms was considered
abnormal.25
In addition, an echocardiogram was performed using an
ATL HDI 5000 (Philips Medical System, Bothell, WA, USA).
Table 1 Characteristics of patients with (HPS) or without
(Non-HPS) hepatopulmonary syndrome.
HPS
(n Z 14)
Non HPS
(n Z 69)
MELD score
(units)
14.0 (8e35) 14.0 (6e40) NS
Exhaled
NO (ppb)
23.7 (9e54.6)
(n Z 12)
17.6 (2.6e56.2)
(n Z 39)
NS
HbCO (%) 2.0 (1e3.9) 1.9 (0.4e8.0) NS
DLCO
(% pred)
66.0 (40.0e91.0)
(n Z 13)
77.0 (51.0e113.0)
(n Z 65)
p < 0.001
DLCO/AV
(% pred)
72.5  18.6
(n Z 13)
86.4  16.1
(n Z 65)
p Z 0.007
AaPO2
(mmHg)
29.5 (23e42.7)
(n Z 12)
15.3 (2.0e40.2)
(n Z 69)
p < 0.001
PaO2
(mmHg)
76.7  12.8 91.8  10.4 p < 0.001
PaCO2
(mmHg)
31.3  3.4 33.8  4.5 p Z 0.054
pH (units) 7.46 (7.41e7.49) 7.44 (7.36e7.55) NS
TLC
(% pred)
86 (63e119) 96.5 (60e134) p Z 0.015
FEV1/VC
(%)
75.4  5.8 76.0  8.9 NS
MELD: model for end-stage liver disease; NO: nitric oxide;
HbCO: carboxyhemoglobin; DLCO: lung diffusing capacity for
carbon monoxide; AV: alveolar volume; AaPO2: alveolar-arterial
oxygen tension difference; TLC: total lung capacity; FEV1:
forced expiratory volume during the first second of expiration;
VC: vital capacity.
1032 I. Enache et al.Quantification of cardiac chamber size was carried out
based on the guidelines of the American Society of
Echocardiography.26
To assess left and right ventricular diastolic function,
mitral and tricuspid pulsed-waveswere used tomeasure peak
early filling velocity (E, cms1), peak lateatrial filling velocity
(A, cms1), E/A ratioandE-wavedeceleration time(EDT,ms).
Tissue Doppler imaging was obtained on the lateral mitral or
lateral tricuspid annulus, and systolic (S, cm s1) and peak
early diastolic velocities (E0, cm s1) were measured.
CCM was defined as altered systolic function at rest
(EF < 55%) or diastolic dysfunction (with or without QTc
prolongation) in the absence of a known cardiac disease or
a known cause of myocardial dysfunction (i.e., coronary
artery disease, diabetes mellitus, systemic hypertension, or
less common diseases, such as hemochromatosis and peri-
cardial fibrosis). Ventricular diastolic dysfunction was
defined as an E/A ratio < 1 and an EDT > 200 ms for pa-
tients under 50 years of age, and >240 ms (LV) or > 220 ms
(RV) for those over 50 years of age.27
Cardiac output (CO; L min1) was calculated using the
formula COZ VTI HR LVOT area, where VTI is the aortic
velocity-time integral, HR the heart rate, and LVOT the left
ventricular outflow track. LVOT area was calculated using
the formula LVOTareaZp r2 (rZ radius) derived from the
measure of the valve annulus diameter. CI (in L min1 m2)
was calculated by dividing CO by the corporeal area.
Tricuspid regurgitation velocity was used (TRV, m s1) to
estimate the systolic arterial pressure (SAP). Normal pul-
monary arterial pressure was defined as a TRV  2.8 m s1
and a SAP  36 mmHg.
Contrast echocardiography (CE) was performed in sub-
jects presenting with an AaPO2 equal to or greater than
20 mmHg28,29 by injecting microbubbles (10 ml of Galac-
tose, Echovist, Bayer Schering, Berlin, Germany) into a
peripheral vein. Positive CE was defined as the appearance
of microbubbles in the chambers of the left side of the
heart in four to six heartbeats after their appearance in the
right heart. The degree of intrapulmonary shunt was graded
from 0 to IV.30 Patients with grades I to IV were considered
to have a significant intrapulmonary shunt (HPS group).
Statistical analysis
The results were expressed as mean  standard deviation
(SD) or median and range (for non-normal distributions).
The comparison between two groups was performed with
Student’s t-test or the ManneWhitney rank sum test (if
normality or equal variance tests had failed). The com-
parison between two percentages was performed using
Fisher’s Exact Test. KaplaneMeier analysis and the log-rank
test were used to evaluate and compare the survival of
patients within four weeks of transplantation. The level of
significance was set at p < 0.05.
Results
Pulmonary assessment
Eighty-three consecutive candidates for OLT (19 women
and 64 men, aged 52.1  10.0 years) were included in thestudy. AaPO2 was equal to or greater than 20 mmHg in 35 of
81 patients. Two patients in whom this parameter was not
measured had very severe hypoxemia and underwent CE,
which confirmed the suspected shunt. Therefore, HPS was
found in 14 of 83 patients (16.9%) included in the study,
representing 34.3% of the patients who had increased
AaPO2 (12/35).
There was no difference in medication between subjects
with and without HPS. The severity of the shunt was: grade
I in six patients, grade II in five, grade III in one and grade IV
(very severe) in two cases. Pulmonary hypertension was
found in two patients with systolic pulmonary arterial
pressures of 40 and 75 mmHg. These two patients were
excluded from further echocardiographic analysis.
No difference in MELD score was noted between the HPS
group and the other patients (Table 1). Moreover, the most
severe cases of shunts did not present high MELD scores (10
and 12).
Table 1 shows the pulmonary function test results. No
difference between the HPS group and other patients was
found regarding exhaled NO, carboxyhemoglobin (COHb)
and pH. As expected, AaPO2 was higher and PaO2 and PaCO2
were lower in the HPS group than in the non-HPS group.
Moreover, single-breath DLCO was lower in the HPS group
than in the non-HPS group.
Four of 81 patients presented with non-contributive
echocardiography (two pulmonary hypertensive patients
were excluded from the analysis, see above). Right heart
Table 2 Echocardiographic data of patients with (HPS) or without (Non-HPS) hepatopulmonary syndrome.
HPS Non HPS HPS Non HPS
Left heart n Z 14 n Z 63 n Z 14 n Z 63
LA (cm) 44.1  4.4 42.3  6.3 E (cm/s) 84.9  23.6 76.4  20.2
LAA (cm2) 23.4  1.7 19.8  3.1a A (cm/s) 77.1  13.5 69.6  19.9
LVEDD (mm) 49.1  3.6 49.6  5.9 E/A 1.12  0.29 1.16  0.39
IVS (mm) 10.0  1.5 10.4  1.5 EDT (ms) 231  32 241  48
LVPW (mm) 9.8  1.8 9.6  1.6 E0 (cm/s) 12.4  2.2 13.3  2.9
LVEF (%) 64  7 65  8 E/E0 7.0  1.6 5.9  2.2
Right heart n Z 14 n Z 56 n Z 14 n Z 50
RVEDD (mm) 26.8  4.3 23.1  6.0b E (cm/s) 57.9  10.1 52.3  12.4
RVEDA (cm2/m2) 9.7  1.6 10.2  2.3 A (cm/s) 55.2  15.0 44.3  13.7
RVESA (cm2/m2) 5.2  1.7 5.1  1.4 E/A 1.11  0.24 1.25  0.38
RVFAC 49  11 47  10 EDT 232  46 248  56
TAPSE (mm) 24.6  3.7 23.4  5.3 E0 (cm/s) 13.9  2.2 13.7  3.6
RAA (cm2) 20.7  3.1 17.8  4.0c E/E0 4.5  1.5 4.0  1.3
LA: left atrium; LAA: left atrium area; LVEDD: left ventricle end-diastolic diameter; LVESD: left ventricle end-systolic diameter; IVS:
interventricular septum; LVPW: left ventricular posterior wall thickness; LVEF: left ventricular ejection fraction; RVEDD: right ven-
tricular end-diastolic diameter; RVEDA: right ventricular end-diastolic area; RVESA: right ventricular end-systolic area; RVFAC: right
ventricular fractional area change; TAPSE: tricuspid annular plane systolic excursion; RAA: right atrial area; E: peak early filling velocity;
A: peak late atrial filling velocity; EDT: E-wave deceleration time; E0 peak early diastolic mitral or tricuspid velocity.
a p Z 0.007.
b p Z 0.043.
c p Z 0.02.
Table 3 Pulmonary and echocardiographic data of pa-
tients with (CCM) or without (Non-CCM) cirrhotic
cardiomyopathy.
CCM
(n Z 15)
Non CCM
(n Z 49)
MELD score (units) 12.7 (6e21) 15.8 (7e40) NS
Exhaled NO (ppb) 20.5 (9e56.2)
(n Z 12)
21.9 (4.4e36.9)
(n Z 30)
NS
HbCO (%)
(all patients)
2.7 (1.4e8.0)
(n Z 15)
1.9 (0.4e4.2)
(n Z 48)
0.02
HbCO (%)
(ex- or
no-smokers)
2.5 (1.4e8.0)
(n Z 12)
1.45 (0.4e3.1)
(n Z 31)
0.01
HPS (n; %) 1; 6.7% 13; 26.5% NS
Smokers (n; %) 3; 20% 17; 34.6% NS
E/A
(left ventricle)
0.83  0.14 1.23  0.32 < 0.0001
E/A
(right ventricle)
1.17  0.29 1.29  0.40 NS
CO (l min1) 5.4  1.3 5.5  1.5 NS
CI (l min1.m2) 2.9  0.8 3.0  0.9 NS
MELD: model for end-stage liver disease; HbCO: carbox-
yhemoglobin; HPS: hepatopulmonary syndrome; MELD: model
for end-stage liver disease; NO: nitric oxide; E: peak early filling
velocity; A: peak late atrial filling velocity; CO: cardiac output;
CI: cardiac index.
Intrapulmonary shunt in liver diseases 1033dimensions and Doppler measurements could not be
assessed with accuracy in seven and 13 patients, respec-
tively. Therefore, complete (i.e., right and left) Doppler
echocardiographic evaluation was obtained for 64 patients
(Table 3).
No case of systolic dysfunction was found. An isolated
left and/or right ventricular diastolic dysfunction was found
in 32 of 64 patients. When patients with a diastolic
dysfunction related to an etiology other than liver disease
were excluded, the global prevalence of CCM was 23.4% (15
of 64 patients), so about half (46.8%) that of patients with
diastolic dysfunction. Treatment with beta-blockers
(especially propranolol for portal hypertension) did not
differ between the CCM and non-CCM groups.
Among all participants, the prevalence of increased QTc
was 28% (23 of 83). No difference in the rate of increased
QTc was observed in HPS vs. non-HPS patients or in CCM (as
defined above) vs. non-CCM patients (data not shown).
Only one patient presented with both moderate HPS
(grade II) and CCM (Table 3). In contrast with what was
observed in the HPS group, a significantly higher COHb was
found in the CCM group, even when excluding smokers
(Table 3).
On comparing patients with or without HPS, we found a
significantly higher left and right atrium area (LAA and RAA)
and a right ventricular enlargement in the HPS group (Table
2).
Patients with HPS presented with a higher cardiac
output (CO) at rest (6.6  1.7 vs. 5.2  1.1 L min1;
p Z 0.007) and cardiac index (CI) (3.6  1.0 vs.
2.8  0.7 L min1 m2; p Z 0.006). Furthermore, the
highest CIs were found in the three patients with a grade III
or IV shunt (4.6; 4.3 and 6.5 L min1 m2 for the grade III and
the two patients with grade IV shunts, respectively). Asignificant correlation was found for the whole set of pa-
tients between CI and both LAA (rZ 0.42; p < 0.0001) and
RAA (r Z 0.32; p Z 0.008).
No correlation was found between hemodynamic data
and MELD score.
1034 I. Enache et al.Outcome before and after OLT
Sixty-eight patients underwent OLT.
Influence of HPS: Global pre- and post-OLT mortality was
not significantly different in patients with or without HPS
[4/14 (28.6%) vs. 11/69 (15.9%), respectively]. However,
there was a tendency (p Z 0.06) for a higher number of
serious adverse events (death or prolonged intensive care,
i.e., length of stay in the intensive care unit of more than
five days) after OLT in the HPS group (3/10) than in the non-
HPS group (5/58) (Fig. 1).
Influence of CCM: Global pre- and post-OLT mortality
was not significantly different in patients with or without
CCM [3/15 (20%) vs. 9/49 (18.4%), respectively]. In the
group of patients who underwent complete echocardio-
graphic evaluation, 52 had OLT. The occurrence of serious
adverse events immediately after OLT did not differ be-
tween CCM (2/12) and non-CCM patients (5/40) (Fig. 1).Discussion
The main results of our study are as follows: i) we observed
a “pure” CCM in 23.4% (n Z 15/64) of the 64 patients with
complete Doppler assessment; ii) HPS was present in 16.9%
(n Z 14/83) of the patients included in our study; iii)
although common factors have been suspected to lead toTime (days)
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Figure 1 Serious adverse events after OLT in patients with or
without HPS (A) and with or without CCM (B). OLT: orthotopic
liver transplantation; HPS: hepatopulmonary syndrome; CCM:
cirrhotic cardiomyopathy; serious adverse events: death or
prolonged intensive care, i.e., length of stay in the intensive
care unit of more than five days.HPS and CCM, there was no relation between these com-
plications in our series of patients; and iv) CCM was not of
prognostic value before or after OLT.
One important finding of our study is that CCM was
detected in 23.4% (n Z 15/64) of patients screened before
OLT and for whom complete echocardiographic assessment
could be obtained. The exact prevalence of CCM is difficult
to determine. Its diagnosis has been defined variously,
based on at rest and/or stress echocardiographic criteria
and/or ECG abnormalities.11,31 More recently, it has been
suggested that brain natriuretic peptide plasma levels
could also be of help.32,33 In our study, CCM was defined as
systolic or diastolic dysfunction at rest and in the absence
of any other clear cause for cardiac impairment. A diagnosis
of CCM was not retained in cases with an isolated increase
in QTc. The prevalence of CCM in our series of patients was
rather high, and we can then conclude that CCM in patients
awaiting OLT is far from rare.
Higher CO, LAA and RAA were found in HPS patients than
non-HPS patients. This is probably mainly explained by the
case of hyperdynamic syndrome found in the group of HPS
patients.16,17 Nevertheless, this increase in cardiac pa-
rameters was not, in our series, related to diastolic
dysfunction, which suggests CCM.
Our results showed that HPS and CCM were not corre-
lated with the severity of hepatic disease. This is not sur-
prising for HPS since it has been reported in previous
studies.28,29 Interestingly, we observed that HPS and CCM
are independent complications of liver disease. This is
rather surprising since identical mechanisms leading to
both complications have been suggested.10,11,15,34e38
As for HPS, the precise pathophysiological mechanisms
leading to CCM have not been fully elucidated. In the
literature, systolic dysfunction in patients awaiting OLT has
been associated with increased endocannabinoid levels,
impaired b-adrenergic receptor signaling, and over-
production of NO or carbon monoxide.10,11,15 Interestingly,
an increase in COHb was noted in patients with CCM in
comparison with other patients, suggesting that carbon
monoxide is implicated in the occurrence of diastolic
dysfunction. It is noteworthy that COHb was increased in
CCM but not HPS patients, which suggests that different
factors may lead to these two complications of liver dis-
eases. It has been reported in animal20,21 and human
studies34e36 that increased NO is one of the factors leading
to HPS or CCM.37,38 In our series we did not observe any
difference in exhaled NO in patients with or without HPS or
in those with or without CCM. This could be explained by
the method used to measure NO (during an expiration rate
of 50 mL min1), which cannot estimate accurately the NO
output from the alveolar compartment, which is the main
source of NO in cirrhosis.34
Clinical studies have shown that HPS is of prognostic
value in patients awaiting liver transplantation, and also
after OLT. In our study, a tendency toward a higher rate of
serious adverse events after transplantation was noted in
HPS patients. The lack of a clearly significant difference
could be explained by the weak statistical power of the
study due to the small number of HPS patients, or by actual
better outcomes due to optimum management of patients
with known HPS during the transplantation period. We
observed an early post-operative mortality of 20% in HPS
Intrapulmonary shunt in liver diseases 1035patients vs. 6.9% in non-HPS patients, which is similar to
what has been reported in other studies.35,36
In contrast to HPS, CCM was not related to prognosis
before and immediately after OLT in the present study. To
the best of our knowledge, this has not been reported
before.
In summary, both HPS and CCM could be found in our
series of patients awaiting OLT, but not in the same pa-
tients. HPS patients were more likely to have a serious
adverse event after OLT than non-HPS patients. Conversely,
CCM was not of prognostic value for survival before and
immediately after OLT, or for the occurrence of adverse
events after OLT. To our knowledge, this is the first study to
evaluate the prevalence and prognostic value of both pul-
monary and cardiac abnormalities in a series of consecutive
patients awaiting OLT.
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